Key result
CETP inhibition emerges as a strategy to substantially raise HDL-C and curb residual CV risk.
Why the study?
Despite statins reducing cardiovascular event rates, many patients remain at risk, necessitating new therapies to reduce residual risk by increasing HDL-C more robustly.
Does CETP inhibition reduce the risk of atherosclerotic disease in at-risk patients?
Does CETP inhibition reduce the risk of atherosclerotic disease in at-risk patients?
CETP inhibition represents a potential novel therapeutic strategy to robustly increase HDL-C and address residual cardiovascular risk in statin-treated patients.
HDL-C adds little to residual risk stratification once LDL-C is very low on potent statins; leaves open whether HDL-targeted therapies reduce events in this population.
Lowering low-density lipoprotein cholesterol (LDL-C) levels with statins is a proven strategy for reducing the risk of atherothrombotic cardiovascular disease (CVD). Yet, despite the success of statins in reducing cardiovascular event rates in at-risk patients, many will still experience further events. There is, therefore, a need to develop suitable therapies to reduce this residual risk. Low high-density lipoprotein cholesterol (HDL-C) levels are an important independent risk factor for CVD. Though fibrates, niacin, and statins have been shown to modestly raise HDL-C, there is increasing recognition of the need to develop therapies that can increase HDL-C more robustly. Such therapies may help supplement the LDL-C-lowering benefits of statins. Inhibition of cholesteryl ester transfer protein (CETP) has been identified as a possible strategy for substantially increasing HDL-C levels and CETP inhibitors have demonstrated clinical efficacy, in terms of increasing HDL-C, in preliminary clinical trials, and clinical trials based on outcomes are ongoing. Two CETP inhibitors, JTT-705 and torcetrapib, are now being evaluated more extensively.
No takes yet. Share an insight, caveat, or question.
Prediman K. Shah (2006) conducted a review in Atherothrombotic cardiovascular disease (CVD). Cholesteryl ester transfer protein (CETP) inhibitors (JTT-705 and torcetrapib) was evaluated. Inhibition of cholesteryl ester transfer protein (CETP) is being evaluated as a novel therapeutic strategy to substantially increase HDL-C levels and reduce residual cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: